Niemann-Pick disease

Recommended panel testing at Breda Genetics for this condition:

Niemann-Pick disease (NPC1, NPC2, SMPD1)

Summary

The eponym Niemann-Pick disease (NPD) encompasses two distinct metabolic defects. The first includes NPD types A and B and is due to deficiency of the acid sphingomyelinase (ASM) enzyme. The second defect, namely NPD type C, is mainly due to accumulation of unesterified cholesterol and glycosphingolipids within the late endosome/lysosome of all cells.

Detailed clinical description

Deficiency of acid sphingomyelinase is usually classified in Niemann-Pick disease types A and B. NPD type A is the neuronopathic form of the disease, characterized by a short period of normal postnatal development followed by severe neurodegeneration which results in death in early childhood. Type A patients exhibit failure to thrive in infancy, hepatosplenomegaly, and profound central nervous system involvement including profound hypotonia and neurodevelopmental delay. About 50% of patients present a characteristic cherry-red spotted macula. Seizures may occur but are not a major sign. Interstitial lung disease is often present and complicated by recurrent respiratory infections. NPD type B is the non-neuronopathic form of the disease, characterized by later onset and milder manifestations compared to NPD type A. Type B patients display a variable degree of systemic involvement, however they do not manifest overt signs of neurodegeneration. Hepatosplenomegaly may be profound and accompanied by liver dysfunction, compromised pulmonary function, hypercholesterolemia and marked decrease of HDL cholesterol. Bruising and epistaxis are frequent, body growth retardation and delayed skeletal age are common findings. Macular halo or cherry-red spots may be observed. NPD type B is compatible with survival until adulthood. Despite the traditional classification, ASM deficiency should be considered as a single entity with a clinical spectrum.

Niemann-Pick disease type C, traditionally sub-divided into type C1, C2, and D, is a lipid storage disorder with a very broad clinical spectrum ranging from a neonatal rapidly progressive fatal disorder to an adult-onset chronic neurodegenerative disease. Patients can be classified into four general categories based on age at neurological onset: the early infantile, late infantile, juvenile, and adolescent/adult onset form. NPD type C is classically a neurovisceral condition. In the severe perinatal form, visceral involvement includes fetal hydrops or fetal ascites accompanied by hepato-splenomegaly and cholestatic jaundice. Lungs involvement may lead to respiratory insufficiency. In the non-perinatal forms, the systemic disease is usually milder.  Typical neurological manifestations include hypotonia in infancy, delay or loss of motor milestones, inevitably evolving into gait problems, ataxia, dysarthria, dysphagia, and variable cognitive impairment. Vertical supranuclear gaze palsy (VSGP), cataplexy, seizures, and dystonia are also common findings. Psychiatric disturbances including dementia and psychosis are often seen in late-onset patients. Visceral and neuropsychiatric course are almost always independent; however, the age of neurological onset is tightly connected to the general course of the disease and, usually, lifespan.

Molecular genetics

Niemann-Pick disease types A and B are caused by bi-allelic mutations in the SMPD1 gene which encodes the ASM enzyme. ASM deficiency may also be diagnosed by detection of residual ASM enzyme activity of less than 10% compared to controls in blood lymphocytes or skin fibroblasts.

Niemann-Pick disease types C is caused by bi-allelic loss-of-function mutations in the NPC1 (NPD type C1 and D) or NPC2 (NPD type C2) genes. Both are involved in the egress of cholesterol from late endosomes or lysosomes. The loss-of-function mutations that cause NPD type C result in the accumulation within the late endosome/lysosome of unesterified cholesterol in visceral tissues, and glycosphingolipids in neurons. Main features of the neuropathology include neuronal storage, neuronal loss, ectopic dendrites, neuroaxonal dystrophy, and Alzheimer-like changes. See also figure 1 for a scheme about the molecualr genetics of Niemann-Pick disease.

Figure 1. Schematic representation of the Molecular Genetics of Niemann-Pick disease.

Differential diagnosis

The genetic differential diagnosis of Niemann-Pick disease includes these main entities:

lysosomal storage diseases such as Gaucher disease (mutations in the GBA gene), hexosaminidase A deficiency (HEXA gene), mucopolysaccharidosis and mucolipidosis, (e.g. IDUA, GNPTAB, MCOLN1 genes), and deficiency of lysosomal acid lipase (LIPA gene),

glycogen storage diseases;

familial hemophagocytic lymphohistiocytosis (STX11, PRF1, UNC13D, STXBP2 genes)

alpha-1 antitrypsin deficiency, due to mutations in the SERPINA1 gene;

– tyrosinemia, due to deficiency of the enzyme fumarylacetoacetase (FAH gene);

mitochondrial disorders, due to mutations in genes encoded by either nuclear or mitochondrial DNA;

maple syrup urine disease (DBT, DLD, BCKDHA, BCKDHB, PPM1K genes);

neuronal ceroid-lipofuscinosis.

The differential diagnosis of adult-onset NPD type C includes also Alzheimer disease.

Recommended testing strategy

A multigene panel based on next-generation sequencing that includes the three genes known to cause Niemann-Pick disease is undoubtedly the faster and more convenient solution. The panel can be based on Mendeliome, clinical exome or full exome sequencing. If a single variant in one of the panel genes is identified, although large deletion/duplications in the NPD genes have been rarely reported, CNV detection can be requested either based on algorithmic NGS data analysis or by MLPA. If the analysis of the panel genes is negative, one may proceed with add-on panels for the differential diagnosis, or upgrade to the analysis and interpretation of the full data acquired.

Recommended panel testing at Breda Genetics for Niemann-Pick disease:

Niemann-Pick disease (NPC1, NPC2, SMPD1)

Bibliography:

Types A and B Niemann-Pick disease. Schuchman EH, Desnick RJ. Mol Genet Metab. 2017 Jan – Feb;120 (1-2):27-33. PMID: 28164782

Niemann–Pick diseases. Vanier MT, Handb Clin Neurol. 2013; 113:1717-21. PMID: 23622394

Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. Benussi A, Cotelli MS, Padovani A, Borroni B.  F1000Res. 2018 Feb 15;7:194. PMID: 29511534

Acid Sphingomyelinase Deficiency. Wasserstein MP, Schuchman EH. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. 2006 Dec 7 [updated 2015 Jun 18]. PMID: 20301544

Niemann-Pick Disease Type C. Patterson M. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. 2000 Jan 26 [updated 2013 Jul 18]. PMID: 20301473

OMIM: #257200, #607616, #257220, #607625

Posted in Academia, Disease cards, Last Update, Medical Genetics and tagged , , , .

Leave a Reply

Your email address will not be published. Required fields are marked *